Ameriprise Financial Inc. grew its position in Grifols, S.A. (NASDAQ:GRFS) by 8.1% during the third quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 2,054,762 shares of the biotechnology company’s stock after purchasing an additional 153,563 shares during the quarter. Ameriprise Financial Inc. owned approximately 0.30% of Grifols worth $44,958,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also recently made changes to their positions in the company. Comerica Bank raised its holdings in shares of Grifols by 1.3% in the 2nd quarter. Comerica Bank now owns 19,062 shares of the biotechnology company’s stock valued at $389,000 after purchasing an additional 245 shares in the last quarter. Advisor Group Inc. raised its holdings in shares of Grifols by 2.8% in the 2nd quarter. Advisor Group Inc. now owns 11,471 shares of the biotechnology company’s stock valued at $242,000 after purchasing an additional 309 shares in the last quarter. Neuberger Berman Group LLC raised its holdings in shares of Grifols by 0.7% in the 2nd quarter. Neuberger Berman Group LLC now owns 47,530 shares of the biotechnology company’s stock valued at $1,004,000 after purchasing an additional 327 shares in the last quarter. Bank of Montreal Can raised its stake in Grifols by 0.7% during the 2nd quarter. Bank of Montreal Can now owns 70,092 shares of the biotechnology company’s stock worth $1,480,000 after acquiring an additional 457 shares in the last quarter. Finally, Wetherby Asset Management Inc. raised its stake in Grifols by 3.0% during the 2nd quarter. Wetherby Asset Management Inc. now owns 18,731 shares of the biotechnology company’s stock worth $396,000 after acquiring an additional 544 shares in the last quarter. Institutional investors and hedge funds own 33.33% of the company’s stock.

Shares of Grifols, S.A. (NASDAQ:GRFS) opened at $22.20 on Friday. Grifols, S.A. has a one year low of $14.33 and a one year high of $24.20. The company has a debt-to-equity ratio of 1.69, a quick ratio of 1.39 and a current ratio of 3.17. The company has a market cap of $5,950.00, a price-to-earnings ratio of 21.07, a P/E/G ratio of 1.66 and a beta of 1.06.

Several equities research analysts recently commented on the stock. UBS lowered shares of Grifols from an “outperform” rating to a “market perform” rating in a research note on Friday, November 24th. Citigroup assumed coverage on shares of Grifols in a research note on Tuesday, October 31st. They set a “buy” rating on the stock. Finally, Zacks Investment Research lowered shares of Grifols from a “buy” rating to a “hold” rating in a research note on Wednesday, October 11th. Two research analysts have rated the stock with a sell rating, three have assigned a hold rating and three have given a buy rating to the company. The company has an average rating of “Hold” and a consensus target price of $24.00.

COPYRIGHT VIOLATION WARNING: This story was first published by Daily Political and is the property of of Daily Political. If you are accessing this story on another website, it was copied illegally and reposted in violation of United States and international copyright and trademark law. The correct version of this story can be accessed at https://www.dailypolitical.com/2017/12/02/ameriprise-financial-inc-has-44-96-million-stake-in-grifols-s-a-grfs.html.

About Grifols

Grifols, SA, a specialty pharmaceutical company, develops, manufactures, and distributes biological medicines on plasma derived proteins in the United States, Canada, Spain, rest of the European Union, and internationally. The company specializes in providing infusion solutions, nutrition products, and medical devices for use in hospitals and clinics.

Institutional Ownership by Quarter for Grifols (NASDAQ:GRFS)

Receive News & Ratings for Grifols S.A. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Grifols S.A. and related companies with MarketBeat.com's FREE daily email newsletter.